KRAS-targeting PROTAC drug passes first clinical test - PubMed
4 hours ago
- #Cancer therapy
- #Targeted therapies
- #Clinical trials
- KRAS-targeting PROTAC drug successfully completes its first clinical test.
- The development focuses on innovative cancer therapy through targeted treatments.
- Research is documented under PMID: 41981113 and DOI: 10.1038/d41591-026-00020-8.
- Key areas include drug discovery and clinical trials for cancer therapies.